IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for cancer and autoimmune diseases.
IMMP | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,
- Website:
- https://www.immutep.com/
Description
Immutep Ltd. is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. As a pioneer in its field, the company focuses on therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's diversified portfolio is designed to harness LAG-3 to either stimulate the immune response to fight cancer or modulate it to combat autoimmune diseases. Its lead product candidate is eftilagimod alfa, a soluble LAG-3 fusion protein under investigation in multiple oncology trials. The company maintains a pipeline of several clinical-stage assets targeting areas of high unmet medical need.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all IMMUTEP Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for IMMUTEP Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for IMMUTEP Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
